MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder
MeiraGTx (MGTX) stock rose 7% after publishing promising results from the first human trial using gene therapy to treat AIPL1-associated severe retinal dystrophy in children. Across all trials so far, ...
stocknews23m
3 Gene Therapy Stocks With Game-Changing Potential
Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
News957m
Medical Minute: Breakthrough treatment helps children with genetic disorder regain vision
A revolutionary gene therapy treatment in London has improved the vision of children suffering from a rare genetic disorder, ...